Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 20/20 | 0.78 |
| ▸ | HTR2A | P28223 | 16/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360256 | 0.99 | HTR2C (0.79) | HTR2CSLC6A4HTR2A | |
| Hydrochloric Acid SCHEMBL360332 | 0.99 | HTR2C (0.77) | HTR2CSLC6A4HTR2A | |
| SCHEMBL14917275 | 0.88 | HTR2C (0.98) | HTR2CSLC6A4HTR2A | |
| SCHEMBL14916793 | 0.88 | HTR2C (1.00) | HTR2CSLC6A4HTR2A | |
| SCHEMBL359975 | 0.88 | HTR2C (0.98) | HTR2CSLC6A4HTR2A | |
| SCHEMBL14916376 | 0.87 | HTR2C (1.00) | HTR2CSLC6A4HTR2A | |
| Hydrochloric Acid SCHEMBL359068 | 0.87 | HTR2C (0.96) | HTR2CSLC6A4HTR2A | |
| SCHEMBL14916639 | 0.87 | HTR2C (0.77) | HTR2CSLC6A4HTR2A | |
| SCHEMBL359089 | 0.87 | HTR2C (0.98) | HTR2CSLC6A4HTR2A | |
| SCHEMBL360479 | 0.87 | HTR2C (1.00) | HTR2CSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | claimed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | claimed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | claimed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | claimed |
| EP-2594559-B1 | PYRAZOLE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-24 | — | — | EP | claimed |
| US-20140315971-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2014-10-23 | — | — | US | claimed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | claimed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | claimed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | claimed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | claimed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | claimed |
| US-20260108494-A1 | THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE | NEUROINNOVATECH APS (DK) | 2026-04-23 | — | — | US | disclosed |
| US-12508244-B2 | Therapeutic agent for non-motor symptoms associated with Parkinson's disease | NEUROINNOVATECH APS (DK) | 2025-12-30 | — | — | US | disclosed |
| US-20230149357-A1 | THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230149357-A1 | THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315971-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HTR2C 1/4885SLC6A4 22/4885HTR2A 7/4885 |
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HTR2C 1/4885SLC6A4 22/4885HTR2A 7/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HTR2C 1/4885SLC6A4 22/4885HTR2A 7/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HTR2C 1/4885SLC6A4 22/4885HTR2A 7/4885 |
| US-20230149357-A1 | THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE | PARK7, SNCA, ACHE | HTR2C 26/4885SLC6A4 16/4885HTR2A 23/4885 |
| US-20260108494-A1 | THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE | PARK7, SNCA, HTR6 | HTR2C 4/4885SLC6A4 60/4885HTR2A 16/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HTR2C 1/4885SLC6A4 22/4885HTR2A 7/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HTR2C 1/4885SLC6A4 22/4885HTR2A 7/4885 |
| US-12508244-B2 | Therapeutic agent for non-motor symptoms associated with Parkinson's disease | PARK7, SNCA, HTR6 | HTR2C 5/4885SLC6A4 78/4885HTR2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.